Real-world safety study of Alhemo in hemophilia
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial will track how well Alhemo works and how safe it is for people with hemophilia A or B in everyday use. If you are 12 or older and your doctor has already decided to start you on Alhemo, this study will collect information to help doctors better understand the medicine's real-world benefits and risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A or hemophilia B
- You are 12 years of age or older
- You have never taken concizumab, or you just started it in the last 12 weeks
- You have not used any other experimental drug in the past 30 days
- You are not allergic to any ingredients in Alhemo
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is tracking how well Alhemo works in people with hemophilia A or B who have developed inhibitors (antibodies that block treatment). It is for patients of any age who have already started taking Alhemo as part of their regular care.
This trial is studying a medication called susoctocog alfa for people with acquired hemophilia A, a bleeding disorder. It aims to understand how well the treatment works and how it is being used.
This program provides access to a new experimental medicine called concizumab for people with hemophilia who cannot use standard treatments. It is designed for patients who have tried other options without success or cannot take them safely.
This trial uses ultrasound to check if healthy joints in people with hemophilia A develop damage while being treated with emicizumab (Hemlibra). It looks at elbows, knees, and ankles over time to see if the medicine prevents joint problems.
This trial tests a new medicine, bometase alfa, to stop bleeding in people with a rare bleeding disorder called acquired hemophilia A. The goal is to control active bleeding episodes safely.
This trial tests emicizumab, a medicine given under the skin, to see how it works in children with hemophilia A. It aims to help control bleeding, no matter if they have inhibitors or not.
Hear when a new Haemophilia A, Haemophilia B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.